Limiting Free Pricing of New Innovative Drugs After Launch: A Necessity for Payers?
Crossref DOI link: https://doi.org/10.1007/s40258-016-0247-0
Published Online: 2016-06-04
Published Print: 2016-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gandjour, Afschin
License valid from 2016-06-04